NCT01830699View on ClinicalTrials.gov

Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis

NACompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Subacromial Bursitis
Interventions
DRUG

Rilonacept

160 mg intra-bursal once

DRUG

Corticosteroid

2 cc (40 mg/mL) triamcinolone intra-bursal once

Trial Locations (1)

39534

Keesler Medical Center, Keesler Air Force Base

All Listed Sponsors
lead

Keesler Air Force Base Medical Center

FED

NCT01830699 - Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis | Biotech Hunter | Biotech Hunter